Moreover, CYP8B1 downregulation, but not CYP7A1,32 decrease in the serum levels of unconjugated BAs and secondary BAs,33 and hepatic BA increase,34 have been reported in patients with MASH. Here, CYP7A1 is linked to metabolic dysfunction-associated steatohepatitis.